Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
Retrieved on:
Tuesday, August 8, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Natural borrowing limit, SBS, Workforce, Endometriosis, Total, IPR, Income tax, Interest, Test Claimants in the Franked Investment Income Group Litigation v IRC, PBC, Graft-versus-host disease, Clinical trial, GAAP, Research, Interest expense, Functional constipation, Short bowel syndrome, Trial of the century, Interstitial cystitis, Primary biliary cholangitis, EBITDA, Acquisition, STARS, Patient, Autoimmune disease, Liver, Depreciation, Phase, FDA, Hand, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Bank, Security (finance), Vaccine, Video game, Reinsurance, Bookkeeping, Ironwood
Ironwood intends to effect a squeeze-out merger under Swiss law to acquire the remaining outstanding VectivBio Shares in the second half of 2023.
Key Points:
- Ironwood intends to effect a squeeze-out merger under Swiss law to acquire the remaining outstanding VectivBio Shares in the second half of 2023.
- Total revenues in the second quarter of 2023 were $107.4 million, compared to $97.2 million in the second quarter of 2022.
- – Ironwood generated approximately $35.0 million in cash from operations in the second quarter of 2023, compared to $61.4 million in cash from operations in the second quarter of 2022.
- Ironwood is increasing its 2023 U.S. LINZESS net sales and total revenue growth guidance and updating its adjusted EBITDA financial guidance.